Evidence map›Paper›PMID 41604611›Full record

ArticleNeurology2026

Association Between Longitudinal Rate of Change in CSF Biomarkers and Subsequent Tau PET Burden in Early Braak Stages.

Nisha Rani, Abhay Moghekar, Daniel D Callow, Kylie H Alm, Corinne Pettigrew, Anja Soldan, Michael Miller, Jiangxia Wang, Martin A Lodge, Marilyn Albert and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nisha RaniDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0003-4667-2534
Abhay MoghekarDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0001-9464-1551
Daniel D CallowDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0003-0843-6602
Kylie H AlmDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0003-0314-1071
Corinne PettigrewDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0003-4264-275X
Anja SoldanDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0002-6193-0418
Michael MillerDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD.ORCID 0000-0003-4689-3855
Jiangxia WangDepartment of Biostatistics, Johns Hopkins School of Public Health, Baltimore, MD; and.ORCID 0000-0002-1715-3981
Martin A LodgeDepartment of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0003-0922-6519
Marilyn AlbertDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0002-8167-8985
Arnold BakkerDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD.ORCID 0000-0003-0417-641X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesChanges in CSF and tau PET biomarkers of Alzheimer disease (AD) emerge years before clinical symptoms are observed. However, few studies have examined the temporal relationship between these measures. This study investigated whether longitudinal changes in CSF AD biomarkers were associated with

methodsThis study involved a retrospective analysis of cognitively unimpaired participants from the longitudinal observational Biomarkers of Cognitive Decline Among Normal Individuals cohort (NIH and Johns Hopkins University). Phosphorylated tau (p-tau) 181, total tau (t-tau), and β-amyloid (Aβ)

resultsA total of 120 cognitively unimpaired individuals (baseline age range 32-78 years; mean age 57 years; 60% female) were included in the analysis, including 78 participants with longitudinal CSF data (424 observations) and 42 additional participants contributing to cross-sectional analyses of initial CSF levels only. Results showed that higher levels of CSF p-tau DISCUSSION: These findings show that tau PET burden in Braak stage I and II subregions is associated with increases in CSF tau and p-tau over time, offering important insights into the relationships among key biomarkers for the diagnosis and staging of AD, although tau PET was collected at only a single time point, limiting inferences about the temporal evolution of PET-CSF relationships.

Indexed as

Alzheimer DiseaseAmyloid beta-Peptidestau ProteinsAdultAgedBiomarkersDisease ProgressionFemaleHumansLongitudinal StudiesMaleMiddle AgedPeptide FragmentsPositron-Emission TomographyRetrospective StudiesAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersMAPT protein, humanPeptide Fragmentstau Proteins

Identifiers

PMID41604611
PMCPMC12857810

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.